Alice Ventures

novoGI Inc. specializes in developing innovative medical devices for gastrointestinal disease management, focusing on solutions that enhance patient care. The company has pioneered a range of nitinol-based compression anastomosis devices, which are designed to facilitate natural reconnection of the intestine following colorectal resection procedures, such as those related to colon cancer treatment. This technology represents a significant advancement in surgical closure methods, utilizing the body's natural healing processes to ensure effective tissue integration. novoGI's products are backed by clinical evidence and have received FDA clearance and CE marking, allowing their use in various healthcare settings. Founded in 1996 and headquartered in Atlanta, Georgia, novoGI also has facilities in Paris, France, and Netanya, Israel, reflecting its global presence in the medical device industry.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

BrainsGate, Ltd. is a medical device company based in Caesarea, Israel, specializing in therapies for patients with central nervous system diseases. The company has developed a technology platform that utilizes electrical stimulation of the spheno-palatine ganglion (SPG) to enhance cerebral blood flow. Currently, BrainsGate is focused on treating acute ischemic stroke through its innovative ischemic stroke system, which involves a miniature electrode implanted in the roof of the mouth during a minimally invasive procedure. This method is performed under local anesthesia and is comparable to standard dental treatments. The company has conducted several clinical trials, including a pivotal trial with 300 patients that validated the safety and efficacy of its treatment. BrainsGate is also engaged in a multi-national, randomized study known as ImpACT-24b, aimed at further assessing the effectiveness of its approach within a critical 24-hour window following a stroke.

Tehuti Networks Ltd. is a fabless semiconductor company based in Herzliya, Israel, founded in 2003. The company specializes in the development of Ethernet network traffic accelerators and Ethernet controllers aimed at facilitating the widespread adoption of 10 Gigabit Ethernet (GbE) technology. Tehuti's products are designed to enhance performance while maintaining low power consumption, making them suitable for a range of applications, including enterprise data centers, IP video servers, and various server platforms. The company's TCP/IP acceleration devices and adapters offer an optimal balance of price and performance, with features such as partial offload mode for simplified integration. Initially supported by the Technion R&D Fund, Tehuti Networks has also secured venture funding from several investors to further advance its technology and market presence.

Mazor Robotics Ltd. specializes in developing, producing, and marketing medical devices designed to enhance surgical procedures in orthopedics and neurosurgery. The company focuses on computer-assisted surgery, which allows for the precise and minimally invasive use of surgical instruments, thereby simplifying complex operations. Its primary offerings include the Mazor X and Renaissance surgical guidance systems, which are utilized in spine surgeries for various applications such as spinal fusion, deformity correction, biopsy collection, tumor excision, and cement augmentation. Founded in 2000 and headquartered in Caesarea, Israel, Mazor Robotics primarily generates revenue from the United States market, aiming to improve patient safety and clinical outcomes during surgical procedures.

Andritz Powerlase Ltd. specializes in the design and manufacture of high-power pulsed lasers tailored for industrial applications, particularly in materials processing. The company provides a range of laser types, including infrared, green, and ultraviolet lasers, which are utilized in various processes such as surface polishing, rust removal, de-painting, laser annealing, and cleaning. Established in 2000 and based in Crawley, United Kingdom, Andritz Powerlase has developed significant expertise in creating advanced solutions for diverse markets, including automotive, aerospace, and defense. The company's technology enables efficient processing for applications like flat panel displays, photovoltaic systems, and microelectronics. Formerly known as Powerlase Photonics Limited, it rebranded in June 2017 and operates as a subsidiary of Andritz AG.

Intense Limited is a manufacturer and supplier of single and multimode monolithic laser array products and high-power laser diodes. The company offers a range of products, including visible and infra-red laser diode components, modules, and systems, as well as laser diode bars and individually addressable laser arrays. Intense Limited also provides foundry services such as front-end wafer processing, back-end assembly, engineering support, and product development. Additionally, the company offers design services in laser diodes, optics, electronics, and packaging. Its products cater to various sectors, including defense and security, medical, consumer and industrial applications, digital printing and imaging, and display technologies. Intense Limited, which was established in 1999 and is headquartered in Glasgow, United Kingdom, operates manufacturing facilities in both the United Kingdom and the United States, and it distributes its products through a network of distributors. The company has also formed a strategic partnership with IQE.

Ignios Ltd., an Oxford, UK-based developer of system-on-a-chip technologies.

Sagitta Ltd. is a technology-based equipment supplier for the fiber optics and semiconductor industries. A core holding of patented technologies in precision automation, machine vision and sub micron polishing has led to the introduction of multiple systems into these markets. The company has introduced the Gemini product series, a platform first in the fiber optics market to integrate the processes of polishing, cleaning and optical metrology on a single platform. Already a leader in failure analysis equipment for the semiconductor and media fields, Sagitta provides an award-winning suite of sample preparation tools used for cross sectional, SEM or TEM semiconductor inspection.

BrainsGate, Ltd. is a medical device company based in Caesarea, Israel, specializing in therapies for patients with central nervous system diseases. The company has developed a technology platform that utilizes electrical stimulation of the spheno-palatine ganglion (SPG) to enhance cerebral blood flow. Currently, BrainsGate is focused on treating acute ischemic stroke through its innovative ischemic stroke system, which involves a miniature electrode implanted in the roof of the mouth during a minimally invasive procedure. This method is performed under local anesthesia and is comparable to standard dental treatments. The company has conducted several clinical trials, including a pivotal trial with 300 patients that validated the safety and efficacy of its treatment. BrainsGate is also engaged in a multi-national, randomized study known as ImpACT-24b, aimed at further assessing the effectiveness of its approach within a critical 24-hour window following a stroke.

SerCoNet is a developer of Ethernet backbone networking solutions for home consumers & SOHOs (Small Office Home Office) over existing telephone wires.

Arakis Limited is engaged in the discovery and development of medicinal products, with a focus on inflammatory diseases and oncology adjunctive therapies. The company specializes in understanding cytokine and receptor-mediated mechanisms of disease, which informs its research and development efforts. Arakis identifies and commercializes product opportunities by exploring new clinical applications for established drugs and drug templates, as well as enhancing the performance of existing medicines. Through its innovative approach, Arakis aims to address unmet medical needs in the therapeutic areas of inflammatory disease and pain.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

Arakis Limited is engaged in the discovery and development of medicinal products, with a focus on inflammatory diseases and oncology adjunctive therapies. The company specializes in understanding cytokine and receptor-mediated mechanisms of disease, which informs its research and development efforts. Arakis identifies and commercializes product opportunities by exploring new clinical applications for established drugs and drug templates, as well as enhancing the performance of existing medicines. Through its innovative approach, Arakis aims to address unmet medical needs in the therapeutic areas of inflammatory disease and pain.